Jefferies trimmed targets on two energy names today. EQT Corporation saw its price target cut to $73 from $75. Baker Hughes lost $3 of target, dropping to $77. Both kept their Buy ratings, but the moves signal caution on the energy complex.
The pharma sector told a different story. Scotiabank raised its target on Merck sharply — from $155 to $180 — while maintaining a Buy. Amgen got an even bigger lift, with its target jumping $50 to $500. Taiwan's August export orders hit a record $103bn, up from $60bn a year earlier. That tech-driven demand wave supports the biotech supply chains both companies rely on.
Warner Bros. Discovery drew a consensus downgrade. The media group lost a Buy rating, shifting the balance toward neutral calls.
In retail, Evercore ISI cut Dollar Tree's target to $135 from $140 on a Hold. The firm moved the other way on , lifting its target to $90 from $85 — also a Hold. Tower REITs and both saw marginal consensus target increases, reflecting steady demand for wireless infrastructure.
DA Davidson initiated Akamai Technologies at Buy with a $150 target.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
